Definium Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Definium Therapeutics Inc in the second quarter 2026?
Definium Therapeutics Inc recorded a cumulative net loss of $-354 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -85.23%.

Within the Legal Cannabis industry 9 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 0 to 3556.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	395.51 %	25.15 %	37.64 %	-50.19 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-354	-238	-184	-168	-115
Return On Equity (TTM)	-85.23 %	-102.48 %	-84.39 %	-86.18 %	-50.24 %
DFTX's Total Ranking	# 3556	# 0	# 0	#	#
Equity (TTM) in Millions	919	279	332	131	185
Seq. Equity Change	229.45 %	-16.09 %	154.47 %	-29.56 %	-16.79 %
Seq. Net Income Change	-	-	-	-	-

Back to DFTX Management Effectiveness >> DFTX's 5 Years Annual ROE >> Compare DFTX ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 10
Sector	# 119
Overall	# 3556

Return On Equity Statistics
High	Average	Low
-33.44 %	-67.84 %	-105.28 %
(Mar 31 2025)		(Mar 31 2024)

DFTX Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2020) 2021
Total Equity in Millions	332	241	78	151	76
Y / Y Equity Change	37.64 %	209.02 %	-48.23 %	98.92 %	-
Net Income in Millions	-184	-109	-96	-57	-34
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-55.3 %	-45.01 %	-122.52 %	-37.63 %	-44.73 %

Back to DFTX Management Effectiveness >> DFTX's 5 Years Annual ROE >> Compare DFTX ROE to its Competitors

More Return On Equity Ratios
Legal Cannabis Industry Roe Trends and Statistics
Consumer Non Cyclical Sector Return On Equity Statistics
DFTX's' Return on Equity at Yahoo Finance
DFTX's Roe Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for DFTX's Competitors
Subscribers only: Roe for Definium Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for DFTX's Customers

Companies with similar Return On Equity at Jun 30 2026, within Consumer Non Cyclical Sector

ROE

Date modified: 2026-09-12T06:26:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.